Validation of a New Scoring System for Treatment Failure in CML Patients on Tyrosine Kinase Inhibitors in a Real-World Setting. [PDF]
Mediterr J Hematol Infect DisMattozzi A +7 more
europepmc +1 more source
Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis
Arthritis &Rheumatology, EarlyView.Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm +2 more
wiley +1 more source
Delayed Cutaneous Ecchymosis with Bruton's Tyrosine Kinase Inhibitors and Breast Radiation: A Case Report. [PDF]
Adv Radiat OncolKim J, Adrianzen Herrera D, Li PC.
europepmc +1 more source
Design, Synthesis, Bioevaluation, and Bioinformatics Study of 5-Benzylidene Hydantoin Derivatives as Novel Tyrosine Kinase Inhibitors. [PDF]
ChemistryOpenNaufal M +4 more
europepmc +1 more source
Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies. [PDF]
BiomedicinesMarino M +8 more
europepmc +1 more source
Adverse reactions of second-line tyrosine kinase inhibitors in advanced hepatocellular carcinoma treatment: a descriptive analysis from WHO-VigiAccess. [PDF]
Transl Gastroenterol HepatolSui W, Duan Y, Cai Z, Xia Y, Li J, Fu J.
europepmc +1 more source
Evaluating the Effectiveness of Tyrosine Kinase Inhibitors on EGFR Mutations In Vitro. [PDF]
Int J Mol SciShao H, Wells A.
europepmc +1 more source
Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for <i>ALK-</i>Mutated NSCLC. [PDF]
JTO Clin Res RepMunarriz BJ +12 more
europepmc +1 more source